High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms

Affiliation auteurs!!!! Error affiliation !!!!
TitreHigh rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms
Type de publicationJournal Article
Year of Publication2015
AuteursEnblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, Girodon F, Andreasson B
JournalEUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume26
Pagination344-347
Date PublishedJUN
Type of ArticleArticle
ISSN0953-6205
Mots-clésEssential thrombocythemia, Myelofibrosis, myeloproliferative neoplasm, polycythemia vera, vascular complications
Résumé

Background: Vascular complications occurring before the diagnosis of myeloproliferative neoplasms (MPN) in 612 patients from four centers in Sweden, Denmark and France were retrospectively studied. Results: Vascular complications were observed in 151 (25%) of the 612 patients. Of these, 66% occurred during the two years preceding diagnosis. The majority of events were thromboembolic (95%), and included myocardial infarction (n = 46), ischemic stroke (n = 43), transient ischemic attack (TIA) (n = 22), deep vein thrombosis/pulmonary embolism (n= 19), splanchnic vein thrombosis (n= 7), and peripheral embolism (n= 7). Bleeding was observed in only 7 (5%) of the 151 patients with vascular events (3 with intracranial bleeding, 2 with epistaxis and 2 with gastrointestinal bleeding). Full blood counts obtained at least 3 months prior to the MPN diagnosis showed that 269 (44%) had abnormal blood values, fulfilling the diagnostic criteria for MPN. During the time from the abnormal blood test to the diagnosis of MPN, 50 patients suffered from a vascular complication. Conclusion: We therefore conclude that a large proportion of MPN patients suffer severe thromboembolic complications prior to diagnosis. If MPN were diagnosed earlier, a large proportion of these events might be prevented. An MPN should always be suspected and ruled out in patients with unexplained elevated hematocrit, leukocyte and/or platelet counts. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

DOI10.1016/j.ejim.2015.03.009